Comparative Pharmacology
Head-to-head clinical analysis: RAUWILOID versus SERPANRAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUWILOID versus SERPANRAY.
RAUWILOID vs SERPANRAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
Serotonin-dopamine activity modulator; partial agonist at 5-HT1A and D2 receptors, antagonist at 5-HT2A receptors.
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
1.5 mg orally once daily at bedtime, titrated up to a maximum of 3 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
Terminal elimination half-life is approximately 62 hours following oral administration, allowing for once-daily dosing.
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Primarily hepatic metabolism via CYP1A2 and CYP3A4, with 18% excreted unchanged in urine and 26% in feces as metabolites.
Category C
Category C
Antihypertensive
Antihypertensive